Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

Stopped early · Phase 1

Conditions studied: Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue

In brief

The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.

Key facts

Study ID

NCT01491594

Run by

Duke University

People needed

1

Starts

2012-04-01

Expected to finish

2013-03-01

Last updated by the study team

2014-04-02

Who can join

Age: 18 and older, up to 82. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic soft tissue or bone sarcoma
• 18 years of age or older
• Adequate blood counts
• Adequate kidney and liver function
• At least 1 but no more than 3 prior systemic therapy regimens for this cancer
• Good performance status - able to carry out work of a light or sedentary nature

You may not qualify if…

• Pre-existing hear disease such as congestive heart failure, or arrhythmia known to increase the risk of thromboembolic events (blood clots)
• Blood clot in the last 6 months, known clotting problem or platelet disorder
• History of brain cancer

Where it is running

• Duke Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.